Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for treating eczema and preparation method of medicine

A drug and eczema technology, applied in the field of medicine, can solve the problems of difficult treatment, large side effects, and easy conversion to hormone-dependent dermatitis, and achieve the effects of reducing the allergy rate, relieving erythema, and preventing allergic allergic reactions.

Inactive Publication Date: 2017-05-24
林维星
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, most of the external medicines for eczema are hormone-based, supplemented by antibiotics. This kind of medicine has side effects and is used repeatedly. It is easy to turn into hormone-dependent dermatitis, and it is more difficult to treat.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] 1) Weigh the oil phase components and heat to 80°C, stir for 20 minutes to obtain the oil phase mixture; the oil phase components include the following raw materials in parts by weight: 1 part of white beeswax, 3 parts of C12-15 benzoate, 1 part of 1 part isopropyl myristate, 1 part melaleuca alternifolia oil, 2 parts stearic acid, 1 part glycyrrhetinic acid, 1 part lanolin, 2 parts shea butter;

[0027] Weigh the water phase components and heat to 80°C, stir for 20 minutes to obtain the water phase mixture; the water phase components include the following raw materials in parts by weight: 4 parts of glycerin, 1 part of diphenhydramine hydrochloride, 60 parts of purified water;

[0028] Weigh the active pharmaceutical component and heat it to 50°C, stir for 20min to obtain the aqueous phase mixture; the active pharmaceutical mixture; the active pharmaceutical component includes the following raw materials in parts by weight: 3 parts of chlorpheniramine maleate, 5 parts o...

Embodiment 2

[0032] 1) Weigh the oil phase components and heat to 85°C, stir for 25 minutes to obtain the oil phase mixture; the oil phase components include the following raw materials in parts by weight: 3 parts of white beeswax, 4 parts of C12-15 benzoate, 3 parts of 1 part isopropyl myristate, 4 parts Melaleuca alternifolia oil, 2 parts stearic acid, 1 part glycyrrhetinic acid, 1 part lanolin, 2 parts shea butter;

[0033] Weigh the water phase components and heat to 85°C, stir for 25 minutes to obtain the water phase mixture; the water phase components include the following raw materials in parts by weight: 7 parts of glycerin, 3 parts of diphenhydramine hydrochloride, 60 parts of purified water;

[0034] Weigh the active pharmaceutical component and heat it to 60° C., stir for 25 minutes to obtain the aqueous phase mixture; the active pharmaceutical mixture; the active pharmaceutical component includes the following raw materials in parts by weight: 5 parts of chlorpheniramine maleate...

Embodiment 3

[0038] 1) Weigh the oil phase components and heat to 85°C, stir for 25 minutes to obtain the oil phase mixture; the oil phase components include the following raw materials in parts by weight: 3 kg white beeswax, 4 kg C12-15 benzoate, 3 kg 1 kg isopropyl myristate, 4 kg melaleuca alternifolia oil, 2 kg stearic acid, 1 kg glycyrrhetinic acid, 1 kg lanolin, 2 kg shea butter;

[0039] Weigh the water phase components and heat to 85°C, stir for 25 minutes to obtain the water phase mixture; the water phase components include the following raw materials in parts by weight: 7 kg of glycerin, 3 kg of diphenhydramine hydrochloride, 60 kg of purified water;

[0040] Weigh the active pharmaceutical component and heat it to 60° C., stir for 25 minutes to obtain the aqueous phase mixture; the active pharmaceutical mixture; the active pharmaceutical component includes the following raw materials in parts by weight: 5 kilograms of chlorpheniramine maleate, 5 kilograms of propylene glycol, 3 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines and relates to a medicine for treating eczema and a preparation method of the medicine. The medicine for treating eczema is specifically prepared from raw materials through mixing in parts by weight as follows: oil phase components: bleached beeswax, C12-15 benzoate, isopropyl myristate, melaleuca alternifolia oil, stearic acid, glycyrrhetinic acid, lanolin and shea butter; water phase components: glycerin, diphenhydramine hydrochloride and purified water; pharmaceutically active components: chlorphenamine maleate, propylene glycol, menthol, camphor, borneol and paeonol. The medicine has the benefits as follows: melaleuca alternifolia oil, menthol, camphor, borneol and other aromatic materials assisting in medicine penetration are added to the medicine and can help glycyrrhetinic acid, chlorphenamine maleate, paeonol and the like to be imported into corium layers of skin, so that the effects of preventing allergy and resisting itching are quickly realized, symptoms such as erythema, skin lesions and the like can be relieved for eczema patients.

Description

technical field [0001] The invention relates to the technical field of medicine, and relates to a medicine for treating eczema and a preparation method thereof. Background technique [0002] Eczema is a skin inflammatory reaction with severe itching caused by various internal and external factors. Divided into acute, subacute and chronic stages. In the acute phase, it tends to exudate, while in the chronic phase, it is infiltrating and hypertrophic. Some patients directly show as chronic eczema. The skin lesions are characterized by pleomorphism, symmetry, itching, and recurrent attacks. [0003] At present, most of the external medicines for eczema are mainly hormones, supplemented by antibiotics. These medicines have side effects and are used repeatedly. They are easy to turn into hormone-dependent dermatitis and are more difficult to treat. Contents of the invention [0004] In order to solve the defects in the above-mentioned prior art, the object of the present in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/56A61K31/4402A61K31/12A61K31/135A61K47/44A61K47/10A61P17/00A61P17/04
CPCA61K31/56A61K31/12A61K31/135A61K31/4402A61K47/10A61K47/44A61K2300/00
Inventor 林维星
Owner 林维星
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com